David Goldstein
#152,795
Most Influential Person Now
Australian oncology researcher
David Goldstein's AcademicInfluence.com Rankings
David Goldsteinmedical Degrees
Medical
#2950
World Rank
#3397
Historical Rank
Oncology
#201
World Rank
#208
Historical Rank
David Goldsteinphilosophy Degrees
Philosophy
#8518
World Rank
#11920
Historical Rank
Logic
#5550
World Rank
#6957
Historical Rank
Download Badge
Medical Philosophy
David Goldstein's Degrees
- PhD Cancer Biology University of Melbourne
Why Is David Goldstein Influential?
(Suggest an Edit or Addition)David Goldstein's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. (2013) (4662)
- Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. (2007) (3726)
- Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. (2010) (1235)
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (2018) (791)
- Identification of metastasis‐related microRNAs in hepatocellular carcinoma (2008) (726)
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. (2016) (707)
- Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. (2012) (691)
- Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells (2004) (560)
- Chemotherapy‐induced peripheral neurotoxicity: A critical analysis (2013) (532)
- Cancer patient preferences for communication of prognosis in the metastatic setting. (2004) (425)
- Pancreatic stellate cells: partners in crime with pancreatic cancer cells. (2008) (419)
- IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C (2010) (397)
- Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. (2014) (314)
- Role of pancreatic stellate cells in pancreatic cancer metastasis. (2010) (305)
- Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. (2005) (285)
- Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. (2014) (273)
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015) (243)
- Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. (1999) (222)
- Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. (2008) (213)
- Oxaliplatin‐induced neurotoxicity and the development of neuropathy (2005) (213)
- Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review (2011) (210)
- Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study (2018) (207)
- Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. (2009) (199)
- Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types (2010) (193)
- Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. (2008) (186)
- The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma (2017) (183)
- STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). (2012) (177)
- Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. (2011) (176)
- Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. (2016) (167)
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial (2015) (166)
- Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. (2011) (161)
- Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. (2009) (158)
- Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy (2017) (155)
- Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. (2013) (150)
- Meta‐analysis of radical resection rates and margin assessment in pancreatic cancer (2015) (149)
- Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. (2009) (145)
- Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. (2007) (145)
- Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. (2009) (141)
- Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). (2013) (136)
- Role of pancreatic stellate cells in chemoresistance in pancreatic cancer (2014) (127)
- Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure (2012) (120)
- Attitudes and information needs of Chinese migrant cancer patients and their relatives. (1999) (119)
- Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. (2017) (115)
- APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. (2019) (115)
- Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. (2015) (114)
- Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. (2012) (109)
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer (2013) (105)
- Are Australian oncology health professionals burning out? A view from the trenches. (2009) (103)
- Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study (2006) (101)
- Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. (1996) (101)
- Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. (2011) (99)
- If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer. (2011) (97)
- Mapping oncology services in regional and rural Australia. (2009) (96)
- Key role of pancreatic stellate cells in pancreatic cancer. (2016) (94)
- Impact of oxaliplatin-induced neuropathy: a patient perspective (2012) (93)
- Understanding community beliefs of Chinese‐Australians about cancer: Initial insights using an ethnographic approach (2005) (92)
- Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. (2013) (90)
- ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. (2009) (87)
- Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer (2009) (86)
- The utility of videoconferencing to provide innovative delivery of psychological treatment for rural cancer patients: results of a pilot study. (2006) (85)
- A bridge between cultures: interpreters’ perspectives of consultations with migrant oncology patients (2010) (84)
- Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients (2015) (84)
- Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer (2016) (84)
- From inside the bubble: migrants’ perceptions of communication with the cancer team (2011) (83)
- Oxaliplatin and Axonal Na+ Channel Function In vivo (2006) (82)
- Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. (2016) (81)
- CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer (2016) (81)
- Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors. (2014) (79)
- Fatigue and psychological distress--exploring the relationship in women treated for breast cancer. (2004) (76)
- Communicating in a multicultural society II: Greek community attitudes towards cancer in Australia (2002) (76)
- Pancreatic cancer: The microenvironment needs attention too! (2015) (75)
- Grappling with cultural differences; communication between oncologists and immigrant cancer patients with and without interpreters. (2011) (74)
- Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. (1996) (74)
- Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. (2019) (72)
- Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. (1998) (71)
- Dose Effects of Oxaliplatin on Persistent and Transient Na+ Conductances and the Development of Neurotoxicity (2011) (71)
- WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. (2009) (68)
- The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study. (2007) (65)
- The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. (2014) (64)
- Interpretation in consultations with immigrant patients with cancer: how accurate is it? (2011) (63)
- Toward cultural competence in cancer genetic counseling and genetics education: Lessons learned from Chinese-Australians (2006) (63)
- Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer (2013) (63)
- Prognostic communication preferences of migrant patients and their relatives (2012) (62)
- Unmet needs in immigrant cancer survivors: a cross-sectional population-based study (2013) (61)
- A randomized controlled trial of a standardized educational intervention for patients with cancer pain. (2010) (61)
- A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). (2010) (60)
- Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report (2004) (59)
- βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer (2014) (57)
- Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey (2017) (56)
- Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP) (2016) (55)
- Primary pancreatic lymphoma – pancreatic tumours that are potentially curable without resection, a retrospective review of four cases (2006) (55)
- Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis (2013) (54)
- A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. (2016) (54)
- Anxiety, depression and quality of life in people with pancreatic cancer and their carers. (2017) (54)
- Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy (2019) (52)
- Modern management of pancreatic carcinoma (2004) (51)
- Clinical supervision and education via videoconference: a feasibility project (2007) (50)
- Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial (2016) (49)
- Education and role modelling for clinical decisions with female cancer patients (2004) (49)
- Inequity in rural cancer survival in Australia is not an insurmountable problem (2006) (49)
- Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. (2018) (48)
- Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. (2016) (47)
- Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer (2017) (47)
- Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer. (2019) (47)
- Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29 (2011) (47)
- Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables. (2015) (46)
- Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer (2016) (46)
- Inferior health-related quality of life and psychological well-being in immigrant cancer survivors: a population-based study. (2013) (45)
- Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer (2007) (45)
- Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer (2017) (45)
- Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. (2014) (44)
- Optimising clinical practice in cancer genetics with cultural competence: lessons to be learned from ethnographic research with Chinese-Australians. (2004) (44)
- Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. (2017) (44)
- Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. (2006) (44)
- Gastrointestinal Stromal Tumours: Correlation of 18F-FDG Gamma Camera-Based Coincidence Positron Emission Tomography with CT for the Assessment of Treatment Response – An AGITG Study (2005) (43)
- A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services (2016) (43)
- Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study. (2014) (42)
- Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. (2011) (42)
- Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence (2016) (42)
- Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. (2013) (41)
- Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations (2014) (40)
- The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. (2013) (40)
- The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). (2016) (40)
- Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. (2005) (40)
- Clinical features and predictors of survival of AIDS‐related non‐Hodgkin's lymphoma in a population‐based case series in Sydney, Australia (2004) (40)
- Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. (2020) (39)
- Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? (2010) (39)
- Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas† (2016) (39)
- Communication with Cancer Patients in Culturally Diverse Societies (1997) (38)
- Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon α (2003) (38)
- Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. (2004) (38)
- Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. (1997) (38)
- Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. (2001) (37)
- Communication challenges experienced by migrants with cancer: A comparison of migrant and English‐speaking Australian‐born cancer patients (2017) (37)
- Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma (1997) (35)
- Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer (2016) (35)
- A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. (2012) (35)
- Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy (2021) (34)
- Multicentric Castleman's disease treated with antivirals and immunosuppressants (2003) (34)
- Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). (2016) (34)
- Enhancing psychosocial care for people with cancer in rural communities: what can remote counselling offer? (2008) (34)
- Alcohol, signaling, and ECM turnover. (2010) (34)
- The Potential of panHER Inhibition in Cancer (2015) (34)
- Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis (2020) (34)
- Should culture affect practice? A comparison of prognostic discussions in consultations with immigrant versus native-born cancer patients. (2013) (34)
- An unusual case of malignant melanoma of the small intestine. (1984) (33)
- Are visiting oncologists enough? A qualitative study of the needs of Australian rural and regional cancer patients, carers and health professionals (2013) (32)
- Information needs of the Chinese community affected by cancer: A systematic review (2017) (31)
- Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. (2006) (31)
- Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition (2020) (31)
- Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial (2015) (31)
- Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy (2011) (30)
- Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. (2015) (30)
- Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). (2019) (30)
- Castleman's disease and HIV infection in Australia (2004) (29)
- INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results. (2015) (28)
- Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. (2014) (28)
- Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. (2020) (27)
- Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals. (2017) (27)
- New molecular and immunotherapeutic approaches in biliary cancer (2017) (27)
- Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade (2019) (26)
- Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer (2018) (26)
- Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study (2015) (26)
- CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. (2019) (26)
- End-stage liver disease and liver transplant: current situation and key issues. (2008) (25)
- Selective Internal Radiation Therapy (SIRT) plus systemic chemotherapy with Irinotecan. A phase I dose escalation study (2005) (25)
- “I might not have cancer if you didn’t mention it”: a qualitative study on information needed by culturally diverse cancer survivors (2015) (25)
- Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. (2011) (23)
- Impact of STAT3 inhibition on survival of osteosarcoma cell lines. (2014) (22)
- Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? (2016) (22)
- Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study (2016) (22)
- Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients (2005) (22)
- Factors associated with quality of care for patients with pancreatic cancer in Australia (2016) (22)
- Informatively missing quality of life and unmet needs sex data for immigrant and Anglo-Australian cancer patients and survivors (2013) (21)
- Exploiting Base Excision Repair to Improve Therapeutic Approaches for Pancreatic Cancer (2015) (21)
- Reaching Further with Online Education? The Development of an Effective Online Program in Palliative Oncology (2010) (21)
- Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. (2016) (21)
- Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience (2004) (21)
- Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. (2019) (21)
- 620PDYOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD) (2017) (20)
- Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review. (2020) (20)
- Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma (2018) (20)
- Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” (2019) (20)
- Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma (2016) (19)
- Determinants of Outcomes Following Resection for Pancreatic Cancer—a Population-Based Study (2016) (19)
- Optimising clinical screening for chemotherapy-induced peripheral neuropathy. (2019) (19)
- A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma. (1998) (19)
- Promising Results of a Cooperative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801) (2005) (19)
- A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer (2008) (19)
- Oncology service initiatives and research in regional Australia. (2015) (19)
- Quantification of Small Fiber Neuropathy in Chemotherapy Treated Patients. (2019) (18)
- Reducing disparity in outcomes for immigrants with cancer: a qualitative assessment of the feasibility and acceptability of a culturally targeted telephone-based supportive care intervention (2013) (18)
- INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)--A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. (2015) (18)
- Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine (2016) (18)
- Perspectives of oncology nurses and oncologists regarding barriers to working with patients from a minority background: Systemic issues and working with interpreters (2018) (18)
- Targeting HGF/c-MET Axis in Pancreatic Cancer (2020) (18)
- Ex vivo culture of intact human patient derived pancreatic tumour tissue (2020) (18)
- Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. (2019) (17)
- When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis (2009) (17)
- Characterization of Fatigue States in Medicine and Psychiatry by Structured Interview (2014) (17)
- Oxaliplatin-Induced Lhermitte’s Phenomenon as a Manifestation of Severe Generalized Neurotoxicity (2009) (17)
- Phase II study of vinflunine in patients with metastatic renal cell carcinoma (2006) (17)
- Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study. (2011) (17)
- Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials (2019) (17)
- Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. (2016) (16)
- Oxaliplatin induces muscle loss and muscle‐specific molecular changes in Mice (2018) (16)
- 3008 ORAL Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04) (2007) (16)
- Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review (2021) (16)
- Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus (2016) (16)
- Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. (2016) (15)
- Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer. (2020) (15)
- It’s all good on the surface: care coordination experiences of migrant cancer patients in Australia (2016) (15)
- Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture (2019) (15)
- Post-cancer fatigue is not associated with immune activation or altered cytokine production. (2012) (15)
- Rituximab to treat gemcitabine-induced hemolytic–uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review (2016) (15)
- The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers (2019) (15)
- Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. (2005) (14)
- A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer (2011) (14)
- The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. (2016) (14)
- Erlotinib (OSI‐774)‐induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon‐α (2007) (14)
- The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer (2018) (14)
- Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer. (2013) (14)
- Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer. (2017) (14)
- Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids12 (2016) (13)
- APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC). (2016) (13)
- CA 19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial ( MPACT ) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer (2016) (13)
- EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. (2015) (13)
- 1139 POSTER Asthenia and Fatigue as Potential Biomarkers of Sunitinib Efficacy in Metastatic Renal Cell Carcinoma (2011) (13)
- Chemotherapy in patients with unresected pancreatic cancer in Australia: A population‐based study of uptake and survival (2018) (13)
- 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. (2008) (13)
- A Cross-Sectional Study of Sub-Basal Corneal Nerve Reduction Following Neurotoxic Chemotherapy (2021) (13)
- Taxane-induced peripheral neuropathy: differences in patient report and objective assessment (2020) (13)
- Interferon-α Promotes the Anti-Proliferative Effect of Gefitinib (ZD1839) on Human Colon Cancer Cell Lines (2005) (13)
- The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer (2011) (13)
- LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival (2021) (13)
- The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer (2020) (12)
- Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds (2018) (12)
- The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC). (2017) (12)
- The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling (2018) (12)
- Cicatricial pemphigoid in non‐Hodgkin's lymphoma (2003) (12)
- TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer (2016) (12)
- Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC). (2014) (12)
- Chemotherapy and peripheral neuropathy (2021) (12)
- Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials (2017) (12)
- Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research. (2017) (12)
- The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer (2020) (12)
- Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma. (1996) (12)
- Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma (2017) (11)
- Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review (2019) (11)
- Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (2015) (11)
- MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity (2016) (11)
- Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) (2007) (11)
- A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. (1997) (11)
- Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG). (2017) (11)
- The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis (2017) (11)
- Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial (2020) (11)
- Barriers and enablers to the implementation of multidisciplinary team meetings: a qualitative study using the theoretical domains framework (2020) (10)
- A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. (2012) (10)
- Using a Delphi process to determine optimal care for patients with pancreatic cancer (2015) (10)
- Electrophysiological and phenotypic profiles of taxane-induced neuropathy (2020) (10)
- Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region. (2020) (10)
- A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy. (2018) (10)
- Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. (2005) (10)
- Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes (2017) (10)
- Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC). (2010) (10)
- S3I-201, a Novel STAT3 Inhibitor, Inhibits Growth of Human Soft Tissue Sarcoma Cell Lines (2013) (10)
- APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA). (2014) (10)
- Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. (2019) (9)
- Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis (2014) (9)
- Challenges and perceived unmet needs of Chinese migrants affected by cancer: Focus group findings (2019) (9)
- Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test (2019) (9)
- The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors (2021) (9)
- LBA-06INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results (2015) (9)
- Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. (2021) (9)
- Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. (2020) (9)
- Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas (2011) (9)
- Initial survival outcomes for the AGITG GAP study – a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC). (2016) (9)
- Antitumor effect of somatostatin analogs in neuroendocrine tumors. (2010) (9)
- A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study. (2015) (9)
- Long-term Quality of Life in patients treated in TROG 01.04: a randomized trial comparing short course and long course preoperative radiation therapy for rectal cancer (2012) (9)
- A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer (2021) (9)
- Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy (2018) (8)
- The impact of anticancer drugs on the ocular surface. (2020) (8)
- Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC) (2005) (8)
- Management of metastatic renal cell carcinoma in the era of targeted therapies (2011) (8)
- Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case‐based approach (2006) (8)
- An educational workshop program for rural practitioners to encourage best practice for delivery of systemic adjuvant therapy. (2006) (8)
- CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC). (2013) (7)
- Biliary Stenting in Patients With Pancreatic Cancer: Results From a Population-Based Cohort Study (2017) (7)
- Chemotherapy influencing the course of nephrotic syndrome in colonic carcinoma (1987) (7)
- Acute changes in nerve excitability following oxaliplatin treatment in mice. (2020) (7)
- Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. (2020) (7)
- Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel (2021) (7)
- Cancer in older people: a tale of two disciplines (2009) (7)
- Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment? (2011) (7)
- Prognosis of Kaposi's sarcoma as an initial and later AIDS associated illness. (1997) (7)
- Oxaliplatin-induced haematological toxicity and splenomegaly in mice (2020) (6)
- Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines. (2018) (6)
- Prolonged survival in a patient with an occult primary small‐cell lung cancer and a solitary brain metastasis at diagnosis (2002) (6)
- COLON Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon a (2003) (6)
- Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer (2020) (6)
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial (2015) (6)
- Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer (2020) (6)
- Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study (2013) (6)
- Diffuse alveolar damage following a single administration of a cyclophosphamide containing chemotherapy regimen. (1997) (6)
- Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial. (2019) (5)
- Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib. (2010) (5)
- Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer. (2018) (5)
- Predictors of resilience in women treated for breast cancer: A prospective study (2012) (5)
- Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer? (2021) (5)
- Cancer survivorship outcomes in immigrants. (2012) (5)
- A PILOT STUDY OF PREOPERATIVE AND POSTOPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER: AUSTRALASIAN GASTROINTESTINAL TRIALS GROUP STUDY 9601 (2007) (5)
- Corneal nerve changes following treatment with neurotoxic anticancer drugs. (2021) (5)
- EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901). (2012) (5)
- Abstract B32: Unmet needs in Chinese, Greek, and Arabic speaking cancer patients in Australia (2009) (5)
- Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer. (2001) (5)
- Consensus approaches to best practice management of gastrointestinal stromal tumors (2008) (5)
- Long term follow-up of CEOP in the treatment of HIV related non-Hodgkin's lymphoma (NHL). (1998) (5)
- Elevated α-foetoprotein and hepatic metastases—it’s not always what it seems! (2002) (5)
- AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer (2021) (5)
- INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG). (2013) (5)
- Describing patterns of care in pancreatic cancer – A population-based study (2015) (5)
- Predictive value of neutrophils count for local tumor control after chemoradiotherapy in patients with locally advanced pancreatic carcinoma. (2021) (5)
- Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). (2013) (4)
- Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC). (2009) (4)
- GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). (2016) (4)
- Cancer Cells Pancreatic Stellate Cells : Partners in Crime with Pancreatic (2008) (4)
- CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress. (2018) (4)
- The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: Anti-angiogenic implications in Pancreatic Cancer (2014) (4)
- TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue (2015) (4)
- Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. (2021) (4)
- An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. (2019) (4)
- Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study (2020) (4)
- Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC). (2016) (4)
- Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer (2018) (4)
- The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia. (2017) (4)
- Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial. (2015) (4)
- Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. (2007) (4)
- P-185Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT (2015) (4)
- Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2017) (3)
- Investigation of Relation of Radiation Therapy Quality Assurance Scores (RTQASc) With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma (LAPC) (2013) (3)
- Advanced cancer patient preferences for receiving molecular profiling results (2020) (3)
- Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study. (2014) (3)
- Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC). (2017) (3)
- Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? (2018) (3)
- 1140 POSTER Asthenia and Fatigue as Predictors of Sunitinib Efficacy in Gastrointestinal Stromal Tumour (GIST) (2011) (3)
- An Orthotopic Resectional Mouse Model of Pancreatic Cancer. (2020) (3)
- Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. (2019) (3)
- Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. (2006) (3)
- Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis. (2020) (3)
- Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses (2019) (3)
- O-0001PHASE III TRIAL (MPACT) OF WEEKLY NAB-PACLITAXEL PLUS GEMCITABINE IN METASTATIC PANCREATIC CANCER: INFLUENCE OF PROGNOSTIC FACTORS ON SURVIVAL (2013) (3)
- CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). (2017) (3)
- Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. (2021) (3)
- EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy (2021) (3)
- Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences (2021) (3)
- Neuroendocrine tumours - models for rare tumour management (2015) (3)
- Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply. (2016) (3)
- A phase II trial of preoperative radiotherapy with protracted infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A multi-center trial for the Trans-Tasman Radiation Oncology Group (2000) (3)
- Determinants of outcomes following resection for pancreatic cancer – An Australian population-based study (2015) (3)
- Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma. (2002) (3)
- Elevated alpha-foetoprotein and hepatic metastases--it's not always what it seems! (2002) (3)
- NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer. (2019) (3)
- The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. (2021) (3)
- 1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study (2021) (3)
- Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial. (2017) (3)
- Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. (2016) (3)
- Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial. (2014) (3)
- Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice. (2021) (3)
- Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer. (2005) (3)
- Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. (2013) (3)
- Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling (2021) (2)
- A prospective cohort study of fatigue after adjuvant therapy for breast cancer: Association with hematologic, endocrine, and immune parameters (2008) (2)
- HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer (2021) (2)
- Chemotherapy and radiotherapy for pancreatic cancer (2000) (2)
- Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review (2017) (2)
- Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics. (2013) (2)
- 1438TiP INTEGRATE IIb: A randomised phase III open label study of regorafenib + nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC) (2021) (2)
- PANCREATIC STELLATE CELLS STIMULATE PANCREATIC CANCER GROWTH AND METASTASIS: FINDINGS OF A NOVEL ORTHOTOPIC MODEL OF PANCREATIC CANCER (2006) (2)
- Overview: regional cancer services in Australia: some evidence of improvement but a long way to go (2007) (2)
- Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis. (2015) (2)
- The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey (2021) (2)
- Post-cancer fatigue is not associated with immune activation or altered cytokine production. (2012) (2)
- Psychosocial outcomes in first-generation immigrant cancer patients in Australia (2012) (2)
- Response of Carney's triad‐related metastatic gastrointestinal stromal tumor to sunitinib (2008) (2)
- Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial (2022) (2)
- Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. (2019) (2)
- Breaking Bad News and Truth Disclosure in Australia (2013) (2)
- Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy (2018) (2)
- Impact of chemoradiotherapy (CRT) on local tumour control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study (2014) (2)
- The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours (2022) (2)
- Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial. (2020) (2)
- Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone. (2015) (2)
- Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901. (2014) (2)
- When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer (2007) (2)
- The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs) (2013) (2)
- The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy (2020) (2)
- Hypersensitivity reactions to oxaliplatin: Can patients be rechallenged? (2006) (2)
- Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcoma. (1996) (2)
- Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial. (2014) (2)
- Delayed relapse following preoperative chemoradiation and surgery for rectal cancer (2003) (2)
- Hepatic expression of lysyl oxidase-like-2 ( LOXL2) in primary sclerosing cholangitis (PSC) (2016) (2)
- barriers to Research with Cancer Patients from Culturally and Linguistically Diverse (cald) Communities in Australia : p3-1 (2007) (2)
- A placebo-controlled trial of Sertraline's effects on symptoms, well-being and survival in advanced cancer: The ZEST Trial (2007) (2)
- 721PA MULTI-CENTRE, PHASE II, OPEN-LABEL, SINGLE ARM STUDY OF PANITUMUMAB, CISPLATIN AND GEMCITABINE IN BILIARY TRACT CANCER: PRIMARY RESULTS OF THE AGITG TACTIC STUDY. (2014) (2)
- Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG). (2016) (2)
- Outpatient treatment with subcutaneous interleukin‐2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience (2005) (2)
- Impact of migrancy on cancer clinical trial participation: Factors associated with approach and consent in Australian‐born versus migrant groups (2020) (2)
- Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group (2011) (2)
- P1310 : Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) – a randomized, multidisciplinary, multinational phase III trial (2015) (1)
- Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy (2018) (1)
- Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework (2020) (1)
- Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer (2020) (1)
- Genetic associations of fatigue and other symptom domains after breast cancer treatment: Results from a prospective cohort study. (2014) (1)
- 6. Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy (2014) (1)
- Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer. (2017) (1)
- Current Care And Needs Of Adult Cancer Survivors-A Cross-sectional Survey Asia Pacific (2012) (1)
- nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT). (2015) (1)
- Chemotherapy made easier. (1993) (1)
- LBA55Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial (2017) (1)
- Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT) (2015) (1)
- 517 - World-First Identification of Circulating Pancreatic Stellate Cells in Metastatic Pancreatic Cancer (2018) (1)
- The successful management of two pregnancies with wild type metastatic gastrointestinal stromal tumors (2009) (1)
- Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer. (2021) (1)
- Erratum to: Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study (2016) (1)
- Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC). (2017) (1)
- Abstract 3763: Treatment of soft tissue sarcoma cells by EGFR and/or STAT3 inhibitors (2012) (1)
- Abstract LB-395: Hepatocyte growth factor: a potential therapeutic target in pancreatic cancer (2011) (1)
- Late fatigue after adjuvant therapy for early breast cancer is largely unrelated to cancer or its treatment: 5 year follow-up of a prospective cohort study (2010) (1)
- Cancer of unknown primary site. (2015) (1)
- Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study. (2020) (1)
- PD-0020CA19-9 DECREASE AND KINETICS IN A RANDOMIZED PHASE III TRIAL (MPACT) OF WEEKLY NAB-PACLITAXEL PLUS GEMCITABINE IN METASTATIC PANCREATIC CANCER (2013) (1)
- The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas (2020) (1)
- Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer (2018) (1)
- The time taken to complete quality of life questionnaires in an advanced cancer trial. (2006) (1)
- Abstract 1655: Mechanism of the synergistic antiproliferative effect of gefitinib and interferon-alpha in sarcoma cell lines (2010) (1)
- PANCREATIC STELLATE CELLS STIMULATE ANGIOGENESIS IN PANCREATIC CANCER AND ACCOMPANY PANCREATIC CANCER CELLS TO DISTANT METASTATIC SITES (2008) (1)
- 1133 PANCREATIC STELLATE CELL AND CANCER CELL DERIVED EXOSOMES IMPAIR BETA CELL FUNCTION: IMPLICATIONS FOR PANCREATIC CANCER RELATED DIABETES. (2020) (1)
- O-0002PROGNOSIS MODEL FOR OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN ANCILLARY STUDY OF THE LAP 07 TRIAL (2014) (1)
- Effect of exercise on neuromuscular toxicity in oxaliplatin‐treated mice (2021) (1)
- Clinical and molecular characterization of HER2amplified-pancreatic cancer (2013) (1)
- 691PREGIONAL SUBANALYSIS OF THE PHASE III MPACT TRIAL: NAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR PATIENTS (PTS) WITH METASTATIC PANCREATIC CANCER (PC). (2014) (1)
- The effects of exercise training on neurophysiology, symptoms, and function in cancer survivors with chemotherapy-induced peripheral neuropathy (2017) (1)
- What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study. (2010) (1)
- 2044 Feasibility of trials to assess safety and toxicity of peri-operative and post-operative adjuvant therapy for hepatic metastases from colorectal cancer (2015) (1)
- EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. (2015) (1)
- Influence of fatigue after breast cancer adjuvant therapy on health care utilization and perceived needs. (2010) (1)
- Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis (2020) (1)
- Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients. (2022) (1)
- Value of whole‐genome sequencing to Australian cancer patients and their first‐degree relatives participating in a genomic sequencing study (2021) (1)
- verview regional cancer services in australia : some evidence of improvement but a long way to go (2015) (1)
- Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies. (2016) (1)
- Disparities in quality-of-life outcomes in immigrant cancer patients. (2012) (1)
- Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling (2021) (1)
- Predictors of care for patients with cancer of unknown primary site in three Australian hospitals (2018) (1)
- Pharmacogenetic factors predicting the need for a higher dose of imatinib. (2010) (1)
- ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer. (2012) (0)
- Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial (2017) (0)
- Compression of liver parenchyma by a malignant hepatic cyst: a previously unreported manifestation of metastatic gastric cancer (2003) (0)
- Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone. (2015) (0)
- Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needs (2013) (0)
- Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836] (2012) (0)
- APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC): 232 (2014) (0)
- Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base. (2022) (0)
- Oxaliplatin-induced chronic changes in sensory nerve excitability (2008) (0)
- The role of chemotherapy in the treatment of pancreatic carcinoma (2005) (0)
- 5. Neurophysiological dysfunction in chemotherapy-treated patients: Comparison of different platinum analogues (2018) (0)
- 746PCOnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT) (2017) (0)
- Early detection of oxaliplatin-induced neurotoxicity: Getting it before it hurts (2008) (0)
- INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG). (2023) (0)
- FILGRASTIM (r-metHuG-CSF, Amgen), CEOP AND ANTIRETROVIRAL THERAPY IN HIV- RELATED NON-HODGKINS LYMPHOMA (NHL) (1994) (0)
- INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) (2023) (0)
- A regional approach to addressing the needs of STEM women academic faculty: Benefits and challenges of a multi-institutional model (2017) (0)
- Syddansk Universitet Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma ( ACTICCA-1 trial )-a randomized , multidisciplinary , multinational phase III trial (2015) (0)
- Targeting a solute carrier to metabolically reprogram tumour-promoting stromal cells in pancreatic cancer (2018) (0)
- 5.14 HIV and Kaposi's sarcoma (1996) (0)
- PHASE I A/B TRIAL OF IMIQUIMOD, AN ORAL INTERFERON INDUCER IN ASYMPTOMATIC HTV POSITIVE INDIVIDUALS (1994) (0)
- 3041 POSTER Oxaliplatin-induced Neurotoxicity – Comparing Four Methods of Assessment (2011) (0)
- ABC; An AGITG trial of fixed dose rate (FDR) gemcitabine (gem) and cisplatin for patients (pts) with advanced biliary tract cancer (ABC) (2007) (0)
- Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis (2020) (0)
- Initial P aclitaxel I mproves O utcome C ompared W ith C MFP Combination C hemotherapy a s F ront-Line T herapy in U ntreated M etastatic B reast C ancer (1999) (0)
- Prognostic score and nomogram to predict overall survival in locally advanced pancreatic cancer (2015) (0)
- Abstract 4416: Significance of IGF-1R and Its signaling pathways in human sarcoma (2011) (0)
- 746TiPAPACT: A PHASE III TRIAL OF NAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR RESECTED PANCREATIC CANCER (PC). (2014) (0)
- Reply to A. Giacalone et al (2012) (0)
- Usefulness of medical oncologists' estimates of survival time in people with advanced cancer. (2012) (0)
- Abstract 1723: Effect and mechanism of PF299804 alone and in combination with STAT3 inhibitor in human sarcoma cell lines (2014) (0)
- Inhibition of both the ligand and receptor of the hepatocyte growth factor/c-MET pathway, in combination with chemotherapy, retards progression of PanIN lesions in KPC mice (2020) (0)
- A Bleak Future for Evidence-Based Radiation Oncology: An Analysis of Phase III Clinical Trials Performed During 2000-2019 (2020) (0)
- Tamoxifen use in retroperitoneal fibrosis (2010) (0)
- Blood Level of Phosphoglycerate Kinase Does not Correlate with Presence or Extent of Tumor (2004) (0)
- Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. (2022) (0)
- Is improving local control sufficient indication for radiotherapy in the management of rectal cancer? A response (2003) (0)
- 334MO Haemoglobin, body mass index and age as risk-factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy (2020) (0)
- Comparable morbidity, mortality and patient long-term survival can be achieved in patients with colorectal liver metastases undergoing 2 stage or downstaging liver resections to patients undergoing routine resections (2014) (0)
- Clinical and statistical prediction: A five and ten year follow-up study of adolescents in a residential treatment center (1991) (0)
- Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2021) (0)
- Combined modality therapy for pancreatic carcinoma: An Australian Pancreatic Cancer Group study of the addition of gemcitabine (G) to concurrent infusional 5-fluorouracil (CI 5FU) and 3D conformal radiotherapy (RT)-Final outcomes. (2016) (0)
- Barriers to Recruitment for a Post-Cancer Fatigue Intervention Study -The TOPS Trial (2013) (0)
- Determinants of attempted resection for patients with non-metastatic pancreatic cancer (2015) (0)
- Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” (2019) (0)
- Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial (2019) (0)
- 184 HEPATOCYTE GROWTH FACTOR/ C-MET PATHWAY INHIBITION COMBINED WITH CHEMOTHERAPY RETARDS PRECURSOR PANINS AND POTENTIATES LOCAL IMMUNITY IN A TRANSGENIC MODEL OF EARLY PANCREATIC CANCER (2021) (0)
- Should culture affect practice? Prognostic discussions with immigrants. (2013) (0)
- Phase I / II trial of filgrastim ( r-metHuG-CSF ) , CEOP chemotherapy and antiretroviral therapy in HFV-related non-Hodgkin ' s lymphoma (2005) (0)
- Compression of liver parenchyma by a malignant hepatic cyst (2003) (0)
- MutY-Homolog modulates pancreatic cancer cell survival and chemoresistance (2016) (0)
- Abstract A113: Mechanisms of gefitinib alone and in combination therapy in soft tissue sarcoma cell lines. (2013) (0)
- Patients’ preferences for adjuvant chemotherapy (ACT) in early colon cancer (ECC): What makes it worthwhile? (2008) (0)
- Patient-derived pancreatic tumours in a dish: implications for real-time precision medicine (2021) (0)
- The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer (2018) (0)
- Abstract C073: CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming (2022) (0)
- What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature (2022) (0)
- Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study (2022) (0)
- Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors (2023) (0)
- Efficacy andsafety ofStealth liposomal doxorubicin inAIDS-related Kaposi's sarcoma (1996) (0)
- 457: Sensory nerve excitability in cancer patients treated with oxaliplatin (2008) (0)
- Anti-tumor effect and mechanisms of concurrent targeting EGFR and metabolism in sarcoma cell lines (2016) (0)
- Uptake of Team Care Arrangements for adults newly diagnosed with cancer. (2022) (0)
- Clinical and molecular profile of young adults with early‐onset colorectal cancer: Experience from four Australian tertiary centers (2022) (0)
- ASCO's Leadership Development Program: Focusing on the Next Generation of Leaders in Asia Pacific. (2023) (0)
- 5. Neurophysiological characteristics in the development and recovery of peripheral neuropathy in oxaliplatin and paxlitaxel treated patients (2020) (0)
- The relationship between the Ocular Surface Disease Index and conventional assessments of chemotherapy-induced peripheral neuropathy (2020) (0)
- Establishment of a novel adjuvant model of orthotopic pancreatic cancer: Effects of HGF-cMET inhibition on disease progression (2019) (0)
- 9. Subclinical peripheral neuropathy prior to chemotherapy in colorectal cancer patients – Myth or reality? (2016) (0)
- βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer (2022) (0)
- Stromal remodeling in pancreatic cancer (2016) (0)
- Pancreatic cancer-related diabetes: Do pancreatic stellate cell and cancer cell derived exosomes play a role? (2020) (0)
- Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors. (2020) (0)
- Targeting the urokinase plasminogen activator (uPA) pathway inhibits pancreatic cancer progression (2021) (0)
- Abstract 3907: Synergistic effect of targeting both CDK4/6 and mTORin sarcoma cell lines (2019) (0)
- Combined modality therapy for pancreatic carcinoma - An Australian Pancreatic Cancer Group study of the addition of gemcitabine to concurrent infusional 5-fluorouracil and 3D conformal radiotherapy (2004) (0)
- Bortezomib Induced Peripheral Neuropathy: A Systematic Review of Phase III Trials (2019) (0)
- Psychological morbidity or unmet needs of cancer patients from culturally and linguistically diverse (CALD) backgrounds. (2007) (0)
- Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results. (2022) (0)
- Correction to "effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers". (2015) (0)
- S1820 Heat Shock Proteins Are Induced During Pancreatic Stellate Cell Activation in Pancreatic Cancer (2009) (0)
- The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling (2018) (0)
- Consensus statement on mandatory measurements in Pancreatic cancer trials for systemic treatment of unresectable disease (COMMPACT) (2017) (0)
- Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link? (2011) (0)
- Gastrointestinal Cancer PrognosticFactorsofSurvival inaRandomizedPhaseIIITrial ( MPACT ) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer (2015) (0)
- P0211 EVERSUN: A phase 2 trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (ANZUP Trial 0901) (2014) (0)
- Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts. (2020) (0)
- Destructive soft tissue metastases in advanced colorectal cancer: a case report. (2021) (0)
- 5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity (2010) (0)
- Combined modality therapy for pancreatic carcinoma - An Australian Pancreatic Cancer Group study of the addition of gemcitabine to concurrent infusional 5-fluorouracil and 3D conformal radiotherapy. (2004) (0)
- Two years of the Australian Rare Cancer Portal: a national referral service for rare cancer information and research. (2022) (0)
- Dummy Run in the Phase III LAP07 Pancreatic Cancer Trial : First Evaluation of Quality of Radiation Therapy Planning (2012) (0)
- CA 19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial ( MPACT ) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients withmetastatic pancreatic cancer (2016) (0)
- Abstract 4531: SWATH-MS profiling identifies prognostic factors for progression-free survival (PFS) In INTEGRATE - A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Gr (2019) (0)
- Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II (2019) (0)
- Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC). (2021) (0)
- Progress in the Treatment of Small Intestine Cancer (2023) (0)
- EJ.2THERAPEUTIC POTENTIAL OF ANGIOGENESIS INHIBITORS FOR GASTRIC CANCER (2013) (0)
- 8. Electrophysiological and phenotypic profiles of taxane-induced neuropathy (2020) (0)
- AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer (2021) (0)
- 3448 Synergistic effects of concurrent inhibition of EGFR and STAT3 in soft tissue sarcoma cell lines (2015) (0)
- Validating innovation: A population-based study of gastrointestinal stromal tumors (GIST) to estimate the survival benefit of imatinib. (2011) (0)
- Medical oncologists’ experience with returning molecular tumor profiling to patients. (2019) (0)
- Phase II trial of paclitaxel in front-line therapy of hormone refractory metastatic prostate cancer (2007) (0)
- What do patients really mean when they complain of fatigue after treatment? Reliable identification of post cancer fatigue: European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO (2013) (0)
- Advances in Treatment Options for Patients with Pancreatic Cancer (2009) (0)
- Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns. (2020) (0)
- Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial (2023) (0)
- PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer. (2012) (0)
- Abstract 5540: Targeting type 1 insulin-like growth factor receptor enhances radiosensitivity in human liposarcoma cell lines (2010) (0)
- Long Term Follow-Up of CEOP in the Treatment of H.I.V. Related N.H.L.: 95 (1997) (0)
- Targeted therapy in soft tissue sarcoma—a novel direction in therapeutics (2013) (0)
- ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. (2009) (0)
- Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU) (2022) (0)
- Pancreatic cancer: Stromal re-programming offers a novel therapeutic approach (2015) (0)
- Fatigue after adjuvant therapy for breast cancer influences health care utilisation and perceived needs (2010) (0)
- P30-24 Mechanisms of axonal dysfunction in acute and chronic oxaliplatin-induced neurotoxicity (2010) (0)
- The impact of gemcitabine chemotherapy and 3D conformal RT/5FU on quality of life of patients managed for pancreatic cancer (2013) (0)
- Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials (2017) (0)
- THO42 A novel method to identify oxaliplatin-induced neuropathy (2008) (0)
- 6147 POSTER A Novel Approach to the Emerging and Frequent Problem of Sustained Long-term Oxaliplatin-induced Neurotoxicity (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David Goldstein?
David Goldstein is affiliated with the following schools:
